Since late 2009, Professor David Cameron has been Professor of Oncology at the University of Edinburgh and Director of Cancer Services for NHS Lothian.
Professor Cameron’s first degree was in mathematics from the University of Cambridge, and he received his medical degree in 1986 from St. George’s Hospital Medical School, London.
After completing a fellowship and MSc in Clinical Oncology at the University of Edinburgh, he received a M.D. with distinction in 1997 and completed his training as a medical oncologist that same year.
Professor Cameron is a member of several professional societies, including the American Society of Clinical Oncology and the European Society for Medical Oncology.
He is also active in a number of clinical trials in breast cancer. He is a member of the executive committee of the HERA adjuvant herceptin trial, and a member of the steering group for several UK adjuvant breast cancer trials.
He is chief investigator on the recently reported UK adjuvant breast cancer trial, TACT2, and of BEATRICE, a global trial that tested the possible benefit of adjuvant bevacizumab in triple negative breast cancer. He jointly chairs the ENCHANT phase II study of an HSP90i in breast cancer.
Professor Cameron has responsibility for oversight and strategy of clinical and translational research in cancer in Edinburgh. He continues his major clinical interest in breast cancer with an ongoing clinical and translational research programme.
He was recently appointed as the Chief Scientist’s Office Clinical Cancer Research Champion in Scotland, to act as a focal point for current and future clinical research in cancer in Scotland.